Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc. (HOWL): 7 pipeline candidates · ~14 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
13.5 months
D/E 3.76 · 2% dilution
Lead: Phase 1/Phase 2
7 candidates
N/A
0 buys · 53 sells (180d)
A transparent, data-derived signal for Werewolf Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$18.0M
Cash
$47.4M
Quarterly Burn
$10.6M
Runway
13.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
46
Total value held
$11.7M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 6,681,307 | $5.6M |
| vanguard capital management llc | 2,435,952 | $2.0M |
| mpm bioimpact llc | 1,208,810 | $1.0M |
| lynx1 capital management lp | 657,786 | $548K |
| sphera funds management ltd. | 626,810 | $522K |
| renaissance technologies llc | 516,218 | $430K |
| geode capital management, llc | 389,487 | $324K |
| bank of america corp /de/ | 264,583 | $220K |
| vanguard fiduciary trust co | 157,726 | $131K |
| millennium management llc | 132,050 | $110K |
Showing top 10 of 46 institutional holders of Werewolf Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Werewolf Therapeutics, Inc.'s pipeline?
Werewolf Therapeutics, Inc. (HOWL) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Werewolf Therapeutics, Inc.'s lead drug candidate?
Werewolf Therapeutics, Inc.'s most advanced tracked candidate is wtx-1011 (Preclinical) for cancer.
What is Werewolf Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Werewolf Therapeutics, Inc. has approximately 13.5 months of cash runway.
What is Werewolf Therapeutics, Inc.'s market capitalization?
Werewolf Therapeutics, Inc.'s market capitalization is approximately $18.0M.
Who is the CEO of Werewolf Therapeutics, Inc.?
Dr. Daniel J. Hicklin Ph.D. is the chief executive officer of Werewolf Therapeutics, Inc. (HOWL).
Get the full picture on Werewolf Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.